A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer

CompletedOBSERVATIONAL
Enrollment

84

Participants

Timeline

Start Date

April 6, 2017

Primary Completion Date

December 20, 2017

Study Completion Date

December 20, 2017

Conditions
Cervical Cancer
Interventions
OTHER

No Intervention

This was an observational study.

Trial Locations (12)

1425

Hospital General de Agudos Juan Antonio Fernandez, Buenos Aires

1437

Hospital General de Agudos J. A. Penna ; Breast Pathology, Buenos Aires

7600

Hospital Privado de Comunidad; Oncology, Mar del Plata

B1650

Instituto Ángel H. Roffo - Universidad de Buenos Aires, Buenos Aires

Unknown

Hospital Julio C. Perrando, Chaco

"Hospital Interzonal General De Agudos Luisa C. de Gandulfo", Lomas de Zamora

CENICLAR, Rosario

Policlínico regional de San Luis, San Luis

Hospital Pablo Soria, San Salvador de Jujuy

F5300COE

Centro Oncologico Riojano Integral (CORI), La Rioja

S2002KDS

Hosp Provincial D. Centenarios; Oncology Dept, Rosario

T4000IAK

Centro Medico San Roque, San Miguel de Tucumán

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03071848 - A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer | Biotech Hunter | Biotech Hunter